ADB-FUBIATA.

ADB-FUBIATA belongs to the wave of cannabinoid receptor agonists that appeared after the Chinese generic ban of 2021: the carboxamide linkage is replaced by an acetamide linkage, that is one methylene more, which is enough to fall outside legal definitions built around carboxamides. In vitro, the molecule fully activates the CB1 receptor, with an efficacy of 141 % relative to CP55,940 and an EC50 potency of 635 nM, and remains practically inactive at CB2. This full agonism is the fundamental difference from THC, which activates CB1 only partially, even though the potency of ADB-FUBIATA is low for the class. In rodents it weakly depresses locomotor activity and does not fully reproduce the discriminative signal of THC, which places it behind the most potent agonists in the series. Human data are lacking: no controlled study, no pharmacokinetics and no published case series concern it specifically. Two preclinical signals nevertheless exist, a computational prediction of blockade of the cardiac hERG channel awaiting experimental confirmation, and a loss of viability of human neuronal spheroids from nanomolar concentrations upwards.

Source

An entirely synthetic molecule, absent from cannabis and from every living organism: it has no connection with hemp or with cannabidiol products. In France it is documented in Mayotte in “la chimique”, the folded papers that contain mostly tobacco: the CHASSE-MAREE protocol detected it in 25 of the 80 samples collected in 2022, second only to MDMB-4en-PINACA, and then in 21 of the 193 samples collected from September 2022 to September 2023 (Richeval et al.; Gish et al.). The same samples contained other synthetic agonists, nicotine, medicines and a synthetic benzodiazepine, bromazolam.

No biosynthetic pathway: the molecule is produced by no living organism and comes from clandestine organic synthesis, described here by chemical class only.

European Union

No control measure at European Union level covers ADB-FUBIATA: no risk assessment has been found on it and the substance has not been added to the annex of Framework Decision 2004/757/JHA, unlike MDMB-4en-PINACA. Its status therefore depends on the law of each Member State. The molecule is, however, monitored by the Union's early warning system run by the European drugs agency, formerly EMCDDA: it appeared on the European market in 2021 and has been identified in materials seized in China, Russia, the United States and Belgium (Deventer et al., 2022). Internationally, it is registered as a new psychoactive substance by the early warning system of the United Nations Office on Drugs and Crime, without appearing in the 1961 Convention or the 1971 Convention (INCB Green List, 35th edition, 2024). By design, it escapes the Chinese generic ban of 2021.

France

ADB-FUBIATA is not listed by name on the French narcotics list: the consolidated list published by ANSM, in its update of 16 February 2026, mentions neither this molecule nor any compound of the acetamide series. Nor is it captured by the generic clauses of the list. The clause covering tetrahydrocannabinols, their esters, ethers and salts as well as the salts of the aforementioned derivatives (in annex III since the decision of 6 February 2026) does not concern it, ADB-FUBIATA not being a tetrahydrocannabinol; and annex IV of the decree of 22 February 1990 rests on a closed list of synthetic cannabinoid skeletons: indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, naphthylmethylindoles, naphthylideneindenes, cyclohexylphenols, indole and indazole carboxamides and carboxylates, pyrrolo[3,2-c]pyridine carboxamides, thiazolylindoles, benzo[c]chromenes. The family of 3-carboxamide indole derivatives presupposes a carboxamide bridge attached directly to carbon 3 of the ring; the additional methylene of ADB-FUBIATA places it outside, and that is exactly the effect sought by the manufacturers. The substance is therefore not scheduled to date, which amounts neither to authorisation for sale nor to a presumption of safety, ANSM revising this list regularly. The products in which it has been found moreover often contained agonists that are themselves scheduled by name: MDMB-4en-PINACA by the decision of 9 December 2021 and ADB-BUTINACA by that of 20 July 2023.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indol-3-yl-acetamide (acetamide-linked analogue of indole-3-carboxamide)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

ADB-FUBIATA (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Deventer M. H. et al., Drug Testing and Analysis, 2022: first selective CB1 agonist circumventing the Chinese generic ban of 2021, ADB-FUBIATA (EC50 635 nM, Emax 141% of CP55,940, CB2 inactive) (new tab)PMID 35570246
2. 2Pulver B., Fischmann S., Gallegos A., Christie R., Drug Testing and Analysis, 2023: the EMCDDA nomenclature framework for synthetic cannabinoids (core, link, linked group and tail codes) (new tab)PMID 36346325
3. 3Deventer M. H. and Stove C. P., Archives of Toxicology, 2025: strategies for circumventing generic bans since the Chinese ban of 2021 (seven scaffolds targeted), including the replacement of the carboxamide link by an acetamide link (ADB-FUBIATA) (new tab)PMID 40983778
4. 4Richeval C. et al., Drug Testing and Analysis, 2024: pharmacological composition of « la chimique » used in Mayotte, CHASSE-MAREE protocol, 80 samples collected in 2022 of which 25 contained ADB-FUBIATA (new tab)PMID 37798946
5. 5Gish A. et al., Environmental Science and Pollution Research, 2025: 193 samples collected in Mayotte from September 2022 to September 2023, of which 21 contained ADB-FUBIATA; human metabolism and tracer for wastewater (new tab)PMID 40576895
6. 6Watanabe S. et al., Archives of Toxicology, 2023: phase I metabolic profile of ADB-FUBIATA, AFUBIATA, CH-FUBIATA and CH-PIATA on human liver microsomes (new tab)PMID 37755504
7. 7Liu X. et al., Rapid Communications in Mass Spectrometry, 2024: metabolism of ADB-FUBIATA in the zebrafish and on human liver microsomes, eighteen metabolites identified (new tab)PMID 38456249
8. 8Hancox J. C. et al., Journal of Molecular and Cellular Cardiology Plus, 2023: cardiac arrhythmia risk of the new synthetic cannabinoids, computationally predicted hERG block most marked for ADB-FUBIATA (new tab)PMID 38143960
9. 9De Simone U. et al., Neurotoxicity Research, 2026: brain cytotoxicity of ADB-FUBIATA on neuronal spheroids derived from human stem cells (new tab)PMID 42461479
10. 10Shetty R. A. et al., Journal of Cannabis Research, 2026: behavioural pharmacology in the rodent of eleven synthetic cannabinoids, including ADB-FUBIATA (new tab)PMID 41526973
11. 11ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026: neither ADB-FUBIATA nor the acetamide series appears there (new tab)
12. 12Order of 22 February 1990 setting the list of substances classified as narcotics, Annex IV (Légifrance) (new tab)
13. 13United Nations Office on Drugs and Crime, early warning advisory, substance record ADB-FUBIATA (new tab)
14. 14PubChem, compound record CID 165361558, ADB-FUBIATA (new tab)
15. 15International Narcotics Control Board, Green List, 35th edition, 2024: ADB-FUBIATA does not appear there (new tab)

SMILES

CC(C)(C)[C@@H](C(=O)N)NC(=O)CC1=CN(C2=CC=CC=C21)CC3=CC=C(C=C3)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.